At Investor Meeting, RXi Updates Pipeline, Discloses Details About Oral-Delivery Tech
October 23, 2008
At Investor Meeting, RXi Updates Pipeline, Discloses Details About Oral-Delivery Tech
In addition to ALS and hypercholesterolemia, RXi has now added Alzheimer’s disease and inflammatory disease to the list of disease areas on which it is focusing. The company, however, made no mention of its work in cancer.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Regulus Selects HCV Drug Candidate, Will Develop without Partner GSK
May 16, 2013 / Gene Silencing News - Scripps, Novartis Team Uncovers New Details of Guide RNA, Argonaute2 Interaction
May 16, 2013 / Gene Silencing News - Gradalis Releases New Clinical Data on Cancer Vaccine
May 16, 2013 / Gene Silencing News - Former Traversa Exec Forms New Company to Develop Oligo-modification Tech
May 16, 2013 / Gene Silencing News - Tekmira on Track to Move Cancer Drug into Phase II, Name New Clinical Candidate in ‘13
May 16, 2013 / Gene Silencing News